Latest Marketable Securities News

Page 2 of 7
Dexus has announced a 19.3 cents per security distribution for HY26, aligned with its updated payout policy, alongside robust financial results and a strategic 10% on-market buyback to address valuation gaps.
Eva Park
Eva Park
27 Feb 2026
ReNerve Limited reported a half-year loss of $2.72 million, up 47% from last year, as it expands its nerve repair product portfolio and secures new regulatory approvals in Asia-Pacific.
Ada Torres
Ada Torres
26 Feb 2026
Imricor Medical Systems saw a sharp 69.5% decline in revenue for 2025, driven by clinical trial impacts, yet narrowed its net loss to $25.3 million as it secured FDA clearance for key products post-year-end.
Ada Torres
Ada Torres
25 Feb 2026
Genesis Energy has completed a NZ$100 million share placement at NZ$2.15 per share, paving the way for a NZ$300 million rights offer to fund its renewable energy expansion under the Gen35 strategy.
Maxwell Dee
Maxwell Dee
24 Feb 2026
Livium Ltd has turned a profit in the first half of FY26 despite lower revenues, supported by cost cuts and a new joint venture. The company also secured $4.5 million in fresh capital to expand its lithium-ion battery recycling and rare earth initiatives.
Maxwell Dee
Maxwell Dee
18 Feb 2026
Dexus has announced a new on-market buyback of up to 10% of its securities, aiming to address the disconnect between its market valuation and underlying asset values while maintaining capital discipline.
Eva Park
Eva Park
18 Feb 2026
SHAPE Australia Corporation Limited reported a robust half-year performance with a 48.5% rise in net profit and declared a fully franked 14 cent interim dividend, underpinned by strategic acquisition and operational discipline.
Victor Sage
Victor Sage
18 Feb 2026
AVITA Medical reported a mixed fourth quarter with revenue pressures easing and full-year growth, underpinned by a new $60 million credit facility and advancing clinical trials.
Ada Torres
Ada Torres
13 Feb 2026
AVITA Medical reported steady Q4 losses amid reimbursement challenges but achieved 11% revenue growth for 2025 and secured a $60 million credit facility to fuel future expansion.
Ada Torres
Ada Torres
13 Feb 2026
AVITA Medical reported an 11% increase in sales revenue for 2025, driven by deeper market penetration and new product launches, while reducing its net loss by 21%. The company secured a $60 million senior secured credit facility but flagged substantial doubt about its ability to continue as a going concern.
Ada Torres
Ada Torres
13 Feb 2026
Bravura Solutions has delivered a robust first half of FY26, posting nearly 10% revenue growth and a significant jump in profitability, while rewarding shareholders with a special dividend. The company also upgraded its full-year guidance, signalling confidence in its growth trajectory.
Sophie Babbage
Sophie Babbage
11 Feb 2026
Global Masters Fund Limited reports steady convertible note activity and a robust loan-to-value ratio of 9.36% for the December 2025 quarter, underscoring its solid financial footing.
Claire Turing
Claire Turing
15 Jan 2026